MARKET

CLLS

CLLS

Cellectis
NASDAQ
3.080
-0.110
-3.45%
Pre Market: 3.330 +0.25 +8.12% 05:31 03/30 EDT
OPEN
3.140
PREV CLOSE
3.190
HIGH
3.250
LOW
3.060
VOLUME
1
TURNOVER
0
52 WEEK HIGH
5.48
52 WEEK LOW
1.100
MARKET CAP
222.81M
P/E (TTM)
-4.5697
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLLS last week (0323-0327)?
Weekly Report · 8h ago
Weekly Report: what happened at CLLS last week (0316-0320)?
Weekly Report · 03/23 09:36
Clear Street Reaffirms Their Buy Rating on Cellectis SA (CLLS)
TipRanks · 03/20 17:35
Cellectis SA Publishes Corporate Presentation on Allogeneic CAR‑T Pipeline and USD 211 million Cash Position
Reuters · 03/20 13:44
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
TipRanks · 03/20 10:29
Cellectis reports FY2025 results with USD 211 million cash as of Dec. 31, 2025
Reuters · 03/19 23:24
Cellectis FY 2025 net loss attributable to shareholders widens 83.86% to USD 67.6 million as revenue rises 75.77% to USD 72.95 million
Reuters · 03/19 23:22
CELLECTIS Q4 REVENUE USD 10.397 MILLION
Reuters · 03/19 23:21
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.